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Aims: Hydrochlorothiazide-induced photosensitivity may increase squamous cell car-
cinoma (SCC), basal cell carcinoma (BCC) and lip cancer risk. The aim was to quantify
these risks.
Methods: Nested case–control studies using data from the UK THIN database from
01 January 1999 to 01 May 2016. Adults with incident SCC, BCC, melanoma, lip can-
cer and oral cancer were matched (on age, sex and calendar year of cohort entry) to
controls using incidence density sampling. Incidence rate ratios (IRR) for each out-
come were calculated for ever and cumulative hydrochlorothiazide exposure, mea-
suring the impact of additionally adjusting for smoking and body mass index (BMI).
Adjusted rate differences were estimated, including the number needed to harm.
Results: Cumulative hydrochlorothiazide doses ≥50 000 mg were associated with a sig-
nificantly increased risk of SCC IRR = 3.05 (1.93–4.81) and BCC IRR = 1.34 (1.06–1.69).
Using a 5-year lag-period, hydrochlorothiazide exposure was also associated with a signifi-
cantly increased risk of lip cancer (IRR 2.85, 95% confidence interval 1.32–6.15). No sig-
nificantly increased risk of melanoma or oral cavity cancer was observed. Following
adjustment for smoking and BMI, which had inverse associations with several skin cancer
types, associations for hydrochlorothiazide remained significant. The overall number
needed to harm with high-dose cumulative hydrochlorothiazide exposure was: 804 for
SCC; 2463 for BCC, and 200 000 for lip cancer but varied by age and sex.
Conclusion: Hydrochlorothiazide exposure was associated with an increased risk of
SCC, BCC and lip cancer that is not explained following adjustment for smoking and
BMI. These findings may support clinical and regulatory decision making.
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1 | INTRODUCTION
Skin cancers including melanoma, squamous cell carcinoma (SCC) and
basal cell carcinoma (BCC) are the most common form of cancer in
humans. The incidence of skin cancer varies across the world but has
increased over time. In the UK, the age-standardised incidence of mel-
anoma, SCC and BCC are 24, 71 and 151 per 100 000 person years
(py) respectively whilst in the USA, the incidence of melanoma and lip
cancer are 22.2 and 0.6 per 100 000 py.1-4 Hydrochlorothiazide
(HCTZ) is commonly prescribed being used by >10 million patients
annually in the USA alone.5,6 HCTZ is primarily used to manage hyper-
tension but also congestive cardiac failure and oedema. HCTZ can
cause photosensitivity and increase UV light-induced DNA damage
that could contribute to skin cancer development.7 In 2013, the Inter-
national Agency for Research on Cancer classified HCTZ as possibly
carcinogenic to humans and called for additional studies to character-
ise skin cancer risk.8
There are limited data examining these risks, particularly among
different population types with variable UV skin susceptibility or phe-
notype.9 Recently published epidemiological studies from Denmark
reported that HCTZ exposure is associated with an increased risk of
developing SCC, BCC and lip cancer, whilst associations with mela-
noma remained less certain.10-12 However, these studies did not con-
tain data on potentially important confounders of smoking and body
mass index (BMI). A safety review of clinical and nonclinical data by
the European Medicines Agency (EMA) Pharmacovigilance Risk
Assessment Committee (PRAC) recently recommended updating the
product information to advise healthcare professionals and patients
about the risk of nonmelanoma skin cancers with HCTZ in Europe
whilst there are currently no such warnings in the USA. The aim of
these studies was to support the PRAC assessment. Their objectives
were to evaluate whether similar associations between HCTZ expo-
sure and skin cancer are observed in a different population and data
source, to assess the impact of adjusting for smoking and BMI and to
estimate absolute risk.
2 | METHODS
2.1 | Data source
The Health Improvement Network (THIN) database contains longitu-
dinal electronic medical records from >600 general practices across
the UK. THIN contains data on general practitioners’ diagnostics and
prescriptions, and lifestyle information. Data are representative of the
UK population in terms of age, sex, deprivation status and geographi-
cal distribution.13 Health information are coded using the Read Code
clinical classification system, a hierarchical classification system, linked
to the International Classification of Diseases.14 Data quality control
measures in THIN include the acceptable mortality reporting date,
which is specific to each practice and defines the date from
which computerised recording of mortality data reached acceptable
standards.15
2.2 | Study design and population
The study used the same designs as the recently published Danish
studies,10-12 with minor deviations representing differences between
databases (supplementary Table S1). Cohort entry was defined as the
latest of the following criteria: start of the study period (01 January
1999); the practices acceptable mortality reporting date; date of regis-
tration with a general practice + 1 year. Cohort exit was defined by
the earliest of the following criteria: an outcome event; deregistration
from the general practice; death; date of last data collection; end of
the study period (01 May 2016). Patients were required to have no
previous cancer diagnosis before the index date, i.e. the date of the
first skin cancer event occurring after cohort entry for case subjects.
For the lip cancer and oral cavity cancer analysis, patients were
allowed to have a prior history of nonmelanoma skin cancer (BCC or
SCC), in keeping with the Danish study. Patients were required to
have no prior record of organ transplantation, human immunodefi-
ciency virus diagnosis or use of immunosuppressant drugs such as
azathioprine, cyclosporine or mycophenolate mofetil, at any time
before the index date that may predispose to skin cancer risk.
2.3 | Outcomes
Outcomes were defined by Read codes recorded in the patient's elec-
tronic medical record (supplementary Table S2). For SCC, we only
used Read codes that were described specifically as being skin related.
Five outcomes were evaluated: SCC skin cancer; BCC skin cancer;
melanoma; lip cancer; and oral cavity cancer. Given that the mecha-
nism of action for this risk is alleged to be photosensitivity, oral cavity
cancer was included as a negative control testing for unmeasured
What is already known on this subject?
• Hydrochlorothiazide can cause skin photosensitivity.
• Recent observational studies have reported an associa-
tion between cumulative hydrochlorothiazide exposure
and skin cancers.
• The generalisability of these findings to other populations
is uncertain.
What this study adds
• In a UK population high-dose cumulative hydrochlorothi-
azide exposure was associated with an increased risk of
squamous cell carcinoma, basal cell carcinoma and lip
cancer.
• The number needed to harm in one year once high-dose
cumulative exposure has occurred was estimated at
804 for squamous cell carcinoma, 2463 for basal cell car-
cinoma and 200 000 for lip cancer but varied by age and
sex.
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confounding because cancers arising within the oral cavity and phar-
ynx will not be exposed to significant UV-light whilst potentially shar-
ing similar risk factors for cancer development and in particular for lip
cancer. Any observed association between HCTZ and oral cavity can-
cers would raise doubt about the validity of an association between
HCTZ and skin cancer due to UV light exposure.
2.4 | Control selection
Controls were randomly selected using incidence density sampling
whereby controls are selected from individuals who have not experi-
enced the event at the index date. For the analysis with lip cancer, up
to 100 controls were randomly selected matched on sex, exact year
of birth and calendar year of cohort entry, applying the same criteria
as described for cases. For the remaining outcomes, up to 20 controls
were randomly selected matched on sex, exact year of birth and cal-
endar year of cohort entry.
2.5 | Exposure
Ever use of HCTZ was defined as having been issued ≥1 prescription
for a HCTZ-containing drug before the index date minus the lag-time
period and never use as never having been prescribed a HCTZ-
containing prescription before the index date minus the lag-time
period. Prescriptions within 2 years of the index date (within the lag-
time period) were excluded from the cumulative dose to allow a rea-
sonable induction period on each cancer outcome, with a secondary
analysis conducted using a 5-year exposure lag-time period to test the
robustness of the results. The dose was identified in all individual eligi-
ble prescriptions, and the cumulative dose for each individual prior the
index date was calculated. For the lip cancer analysis, high-dose HCTZ
use was defined as a cumulative dose ≥25 000 mg, corresponding to
1000 or more defined daily doses (i.e. approximately 3 years of cumu-
lative use). For the remaining outcomes, high-dose HCTZ was defined
as a cumulative dose ≥50 000 mg, corresponding to 2000 or more
defined daily doses (i.e. approximately 6 years of cumulative use).
These were chosen to replicate the recently published Danish stud-
ies.10-12 The list of HCTZ drug codes is contained in Table S3.
2.6 | Confounders
The primary analyses were adjusted for: (i) age and sex (inherent in
the matching criteria); any use of the following drugs with suggested
photosensitizing properties (retinoids, tetracyclines, macrolides,
quinolones, amiodarone); (ii) any use of the following drugs with
suggested antineoplastic effects (aspirin, nonsteroidal anti-
inflammatory drugs and statins); (iii) history of alcohol abuse, diabetes
and chronic obstructive pulmonary disease; (iv) the Charlson comor-
bidity index score (categorised as 0: low; 1–2: medium; or ≥ 3: high).
Exposure to each potential confounder drug was defined as ≥2 pre-
scriptions on separate dates. Covariate information on drugs recorded
less than 2 years prior to the index date was disregarded. For model
2, we additionally adjusted for smoking status (nonsmoker, ex-smoker
and current smoker) and BMI.
2.7 | Data analysis
Conditional logistic regression was used to calculate odds ratios for
the association between each cancer outcome and the cumulative
dose categories. Using an incidence density sampling approach, odds
ratios calculated in this way represent incidence rate ratios (IRR) that
we use to report the effect estimates. Associations are first pres-
ented using a 2-year HCTZ exposure lag-time and then using a
5-year HCTZ exposure lag-time. Given the amount of person follow-
up in THIN is less than in the Danish registries, associations were
evaluated using all patients with sensitivity analysis using patients
restricted to those with at least 10 years follow-up. Analyses are first
presented matched on exact age and sex only, then adjusted using
the approach applied in the Danish studies (adjusted model 1), and
by additionally adjusting for smoking status and BMI (adjusted model
2). Multiple imputation was used to impute missing data on smoking
and BMI and the imputation model included all variables relating to
clinical characteristics, outcome events, medication, and com-
orbidities. Multiple imputation used fully conditional specification,
with linear regression for continuous variables (BMI) and logistic
regression for categorical variables (smoking status) with 5 imputa-
tions and analysed using Rubin's rules.16 Adjusted rate differences
were calculated for significant associations as described.17 As the
incidence of SCC in the cohort was less than expected, absolute risk
estimates for SCC were calculated using published incidence rates
rather than the cohort data.3 In this regard, the adjusted rate differ-
ence for SCC was calculated by (IR × IRR) – IR. Rate differences were
then used to estimate the number of patients needed to treat to
cause 1 additional cancer (number needed to harm) per year overall,
and by sex and age category, as reported elsewhere, for high dose
cumulative HCTZ exposure.18,19 Analysis was carried out using SAS
Enterprise Guidev7.1 and STATAv15.
2.8 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY, (Harding et al., 201820) and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20.
3 | RESULTS
3.1 | Nested case control populations
Characteristics of cases and controls are presented in Table 1. A total
of 7560 incident SCC cases were identified during cohort follow-up
(incidence 11.7 per 100 000 py in adults), which were matched to
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151 194 controls. The number of cases and controls fell to 4,401 inci-
dent SCC cases and 88 449 controls when patients were required to
have at least 10 years of follow-up.
A total of 89 088 incident BCC cases were identified during
cohort follow-up (incidence 137.5 per 100 000 py in adults), which
were matched to 1 781 712 controls. The number of cases
and controls fell to 31 253 incident BCC cases and 625 004 con-
trols when patients were required to have at least 10 years of
follow-up.
A total of 11 185 incident melanoma skin cancer cases were iden-
tified during cohort follow-up (incidence 17.9 per 100 000 py in
adults), which were matched to 223 700 controls. The number of
cases and controls fell to 3831 incident melanoma cases and 76 656
controls when patients were required to have at least 10 years of
follow-up.
A total of 707 incident lip cancer cases were identified during
cohort follow-up (incidence 1.1 per 100 000 py in adults), which were
matched to 70 500 controls. The number of cases and controls fell to
179 incident lip cancer cases and 18 202 controls when patients were
required to have at least 10 years of follow-up.
A total of 3516 incident cases of oral cavity cancer were identi-
fied during cohort follow-up (incidence 5.7 per 100 000 py in adults),
which were matched to 70 328 controls. The number of cases and
controls fell to 1277 incident cases of oral cavity cancer and 25 537
controls when all patients were required to have at least 10 years of
follow-up. All patients were well matched on age, sex and follow-
up time.
3.2 | Relative risk of skin, lip and oral cavity
cancers with hydrochlorothiazide exposure
The relative incidence of SCC was significantly elevated with ever use
of HCTZ (IRR =1.22, 95%CI 1.02 to 1.45; Table 2). When stratified by
dose, the relative incidence of SCC was significantly elevated with
cumulative doses ≥50 000 mg (IRR = 2.93, 95%CI 1.85 to 4.62).
Adjustment for smoking status and BMI did not alter the significance
of these associations.
The relative incidence of BCC was significantly elevated with ever
use of HCTZ (IRR 1.08, 95%CI 1.01 to 1.15; Table 2). When stratified
by dose, the relative incidence BCC was elevated with cumulative
doses ≥50 000 mg (IRR = 1.30, 95%CI 1.03 to 1.65). When adjusted
for smoking status and BMI, cumulative doses ≥50 000 mg remained
significantly elevated.
The relative incidence of melanoma was not significantly elevated
with ever use of HCTZ (Table 2). When stratified by dose, the relative
incidence of melanoma was not significantly elevated with high-dose
HCTZ use. Adjustment for smoking status and BMI did not alter the
significance of these associations.
The relative incidence of lip cancer was nonstatistically signifi-
cantly elevated with HCTZ exposure (IRR 1.61, 95%CI 0.71–3.66
and 2.23, 95%CI 0.54–9.16 with 1–24 999 mg and ≥25 000 mg
cumulative HCTZ exposure respectively, Table 2). Adjustment for
smoking status and BMI did not alter the significance of these
associations. The relative incidence of oral cavity cancer was not
significantly elevated with HCTZ exposure (Table 2). Adjustment
for smoking status and BMI did not alter the significance of these
associations.
3.3 | Secondary analysis
Secondary analyses using the 5-year lag-time are shown in Table 3.
Using a 5-year lag-time, the association between HCTZ and lip cancer
was significantly elevated (IRR = 2.59, 95%CI 1.20 to 5.60) with
1–24 999 mg cumulative exposure; Table 3). Given the reduced
power, it was not possible to estimate the association with cumulative
doses ≥25 000 mg using a 5-year lag-time. Other associations exam-
ined using a 5-year lag-time were generally in keeping with those
using the 2-year lag-time apart from the association with SCC,
which was also significantly elevated at lower cumulative doses
(≥25 000 mg).
3.4 | Sensitivity analysis
Associations restricting to patients with at least 10 years follow up
are presented in Tables S4 and S5. These effect estimates were similar
to the primary and secondary analyses but were less precise due to
loss of information.
3.5 | Absolute risk of SCC, BCC and lip cancer with
hydrochlorothiazide exposure
Adjusted rate differences per 100 000 patients for incident SCC, BCC
and lip cancer are presented in Table 4. Cumulative exposure to
≥50 000 mg of HCTZ was estimated to cause 124 additional cases of
SCC per 100 000 py, 40 additional cases of BCC per 100 000 py and
1 additional case of lip cancer per 200 000 py. The absolute risk was
greater in people aged 60 years and over (383 additional cases of SCC
per 100 000 py, 162 additional cases of BCC per 100 000 py and > 5
additional cases of lip cancer per 200 000 py). Depending on the cate-
gory evaluated, the number needed to harm per year ranged from:
261 to 4167 for SCC; 618 to 3610 for BCC; and 37 037 to 500 000
for lip cancer.
3.6 | Association of skin, lip and oral cavity cancer
with smoking and BMI
The associations between the different cancers and smoking and BMI
are shown in Table 5. Smoking was associated with a significantly
increased risk of lip and oral cavity cancers. In contrast smoking was
inversely associated with BCC and melanoma risk. There were no
strong associations with smoking and SCC. A BMI of ≥30 kg/m2 was
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associated with a significantly reduced risk of SCC, BCC, melanoma
and oral cavity cancer.
4 | DISCUSSION
We found that HCTZ exposure was associated with a significantly
increased relative incidence of SCC, BCC and lip cancer that varied
according to cumulative HCTZ dose and definition of the exposure
lag-time period used. However, whilst no significantly increased risk
was observed with melanoma, a small increase cannot be excluded
based on the available data.
The main studies investigating HCTZ and skin cancer were con-
ducted in Denmark were cumulative HCTZ exposure of ≥50 000 mg
was associated with a 1.3-fold increased risk of BCC and a 4-fold
increased risk of SCC.10 Our study demonstrated similar sized effect
estimates for BCC and SCC associated with ≥50 000 mg of
TABLE 2 Association between hydrochlorothiazide exposure and skin, lip and oral cavity cancer using a 2 year lag-time
All patients Cases Controls Crude IRRa Adjusted IRRb Adjusted IRR with smoking & BMIc
Squamous cell carcinoma
Nonuse 7420 149 313 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 140 1881 1.50 (1.26–1.78) 1.22 (1.02–1.45) 1.25 (1.05–1.48)
Cumulative amount (mg)
▪ 1–24 999 89 1403 1.28 (1.03–1.59) 1.03 (0.83–1.28) 1.05 (0.84–1.30)
▪ 25 000–49 999 29 347 1.69 (1.15–2.47) 1.38 (0.95–2.03) 1.44 (0.98–2.11)
▪ ≥50 000 22 131 3.40 (2.16–5.35) 2.93 (1.85–4.62) 3.05 (1.93–4.81)
Basal cell carcinoma
Nonuse 88 130 1 766 158 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 958 15 554 1.24 (1.16–1.32) 1.08 (1.01–1.15) 1.10 (1.03–1.17)
Cumulative amount (mg)
▪ 1–24 999 714 11 756 1.13 (1.04–1.24) 1.06 (0.98–1.14) 1.08 (0.995–1.16)
▪ 25 000–49 999 169 2758 1.21 (1.03–1.43) 1.08 (0.92–1.26) 1.10 (0.94–1.29)
▪ ≥50 000 75 1040 1.42 (1.10–1.84) 1.30 (1.03–1.65) 1.34 (1.06–1.69)
Melanoma
Nonuse 11 099 222 293 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 86 1407 1.23 (0.99–1.53) 1.11 (0.89–1.38) 1.09 (0.88–1.36)
Cumulative amount (mg)
▪ 1–24 999 66 1081 1.23 (0.95–1.57) 1.11 (0.86–1.42) 1.08 (0.85–1.40)
▪ 25 000–49 999 16 246 1.31 (0.79–2.17) 1.18 (0.71–1.96) 1.17 (0.70–1.94)
▪ ≥50 000 4 80 1.00 (0.37–2.74) 0.90 (0.33–2.45) 0.89 (0.33–2.43)
Lip cancer
Nonuse 699 70 047 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 8 453 1.78 (0.88–3.61) 1.63 (0.80–3.33) 1.77 (0.88–3.61)
Cumulative amount (mg)
▪ 1–24 999 6 345 1.75 (0.78–3.95) 1.61 (0.71–3.66) 1.82 (0.80–4.14)
▪ 25 000–49 999 2 108 2.35 (0.58–9.59) 2.23 (0.54–9.16) 2.12 (0.52–8.74)
▪ ≥50 000 0 22 - - -
Oral cavity cancer
Nonuse 3490 69 802 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 26 518 1.00 (0.68–1.49) 0.84 (0.56–1.26) 0.90 (0.60–1.36)
Cumulative amount (mg)
▪ 1–24 999 22 387 1.14 (0.74–1.75) 0.94 (0.60–1.46) 1.01 (0.64–1.57)
▪ 25 000–49 999 3 104 0.58 (0.18–1.82) 0.51 (0.16–1.61) 0.53 (0.17–1.69)
▪ ≥50 000 1 27 0.74 (0.10–5.46) 0.74 (0.10–5.50) 0.88 (0.12–6.58)
aMatched on sex and age only. bAdditionally adjusted for; any use of selected drugs with suggested photosensitizing properties (retinoids, tetracyclines,
macrolides, quinolones, amiodarone); any use of drugs with suggested antineoplastic effects (aspirin, nonsteroidal anti-inflammatory drugs, and statins);
history of alcohol abuse, diabetes and chronic obstructive pulmonary disease; the Charlson comorbidity index. cAdjusted for confounders in B plus smoking
status and BMI.
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cumulative HCTZ exposure. Although Pottegård et al. reported a sig-
nificant 1.2-fold increased risk with ≥50 000 mg of cumulative expo-
sure and malignant melanoma, no dose–response relationship was
observed and the clinical implication of the results are less uncer-
tain.12 We found no significant association between HCTZ exposure
and melanoma although we were not able to evaluate the association
between melanoma and ≥50 000 mg cumulative HCTZ dose ade-
quately due to estimates being less precise. Two earlier Danish studies
assessing melanoma risk with HCTZ reported contrasting results with
1 reporting a 1.4-fold significantly increased risk of melanoma whilst
the other found no significant association.21,22
One recent Danish study reported a 2-fold increased risk of lip
cancer with ever use of HCTZ, and a 4-fold increase with ≥25 000 mg
of cumulative exposure11 We observed similar sized effect estimates
in the primary analysis although they were not statistically significant.
However, when the lag-time prior to the index date was increased the
observed associations between lip cancer and HCTZ exposure were
strengthened, as occurred in the Danish study, and became
TABLE 3 Association between hydrochlorothiazide exposure and skin, lip and oral cavity cancer using a 5 year lag-time
All patients Cases Controls Adjusted IRRa Adjusted IRRb Adjusted IRR with smoking and BMIc
Squamous cell carcinoma
Nonuse 7458 149 791 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 102 1403 1.46 (1.19–1.79) 1.19 (0.97–1.46) 1.22 (0.99–1.50)
Cumulative amount (mg)
▪ 1–24 999 68 1131 1.21 (0.95–1.55) 0.98 (0.76–1.25) 0.99 (0.77–1.27)
▪ 25 000–49 999 23 204 2.27 (1.48–3.50) 1.90 (1.23–2.94) 2.00 (1.30–3.09)
▪ ≥50 000 11 68 3.27 (1.73–6.20) 2.77 (1.46–5.29) 2.91 (1.53–5.55)
Basal cell carcinoma
Nonuse 88 437 1 770 860 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 651 10 852 1.20 (1.11–1.30) 1.04 (0.96–1.13) 1.06 (0.98–1.15)
Cumulative amount (mg)
▪ 1–24 999 523 8708 1.20 (1.10–1.32) 1.04 (0.95–1.13) 1.06 (0.97–1.16)
▪ 25 000–49 999 82 1547 1.06 (0.85–1.33) 0.93 (0.74–1.16) 0.95 (0.76–1.18)
▪ ≥50 000 46 597 1.55 (1.14–2.09) 1.41 (1.04–1.90) 1.44 (1.07–1.95)
Melanoma
Nonuse 11 123 222 759 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 62 941 1.32 (1.02–1.71) 1.19 (0.92–1.54) 1.18 (0.91–1.53)
Cumulative amount (mg)
▪ 1–24 999 50 768 1.31 (0.98–1.74) 1.18 (0.88–1.57) 1.16 (0.87–1.55)
▪ 25 000–49 999 11 127 1.74 (0.94–3.23) 1.58 (0.85–2.93) 1.57 (0.85–2.92)
▪ nu 50 000 1 46 0.44 (0.06–3.16) 0.38 (0.05–2.75) 0.37 (0.05–2.69)
Lip cancer
Nonuse 700 70 214 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 7 286 2.48 (1.16–5.29) 2.15 (1.00–4.63) 2.31 (1.07–4.97)
Cumulative amount (mg)
▪ 1–24 999 7 240 2.96 (1.38–6.32) 2.59 (1.20–5.60) 2.85 (1.32–6.15)
▪ ≥25 000 0 46 - - -
Oral cavity cancer
Nonuse 3497 69 968 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ever use 19 360 1.06 (0.67–1.68) 0.89 (0.56–1.44) 0.96 (0.60–1.55)
Cumulative amount (mg)
▪ 1–24 999 17 298 1.14 (0.70–1.87) 0.95 (0.57–1.56) 1.00 (0.60–1.67)
▪ ≥25 000 2 62 0.65 (0.16–2.65) 0.62 (0.15–2.56) 0.73 (0.18–3.01)
aMatched on sex and age only. bAdditionally adjusted for; any use of selected drugs with suggested photosensitizing properties (retinoids, tetracyclines,
macrolides, quinolones, amiodarone); any use of drugs with suggested antineoplastic effects (aspirin, nonsteroidal anti-inflammatory drugs and statins);
history of alcohol abuse, diabetes and chronic obstructive pulmonary disease; the Charlson comorbidity index. cAdjusted for confounders in B plus smoking
status and BMI.
MORALES ET AL. 7
significant. The lag-time period is the period in which any exposure is
assumed to mechanistically be noncausal due to the potential latency
required for skin cancer development. Therefore, during such a lag-
time period any prescriptions for HCTZ are disregarded.
We evaluated oral cavity cancer as a negative control to test the
potential mechanism that photosensitivity specifically increases the
risk of skin cancers. We consistently found no elevated association
between HCTZ exposure and incident oral cavity cancer development,
suggesting that unmeasured confounding by risk factors common to
skin/lip cancer and oral cavity cancer does not explain the observed
associations.
4.1 | Strengths and weaknesses of the study
Although our analyses attempted to replicate the Danish studies in
another European data source and population, the available power for
analysis and subtle differences between databases, covariates and
method of diagnosis may have influenced the strength of observed
associations. The THIN database is a large data source but it does not
have the same national coverage or longitudinal follow-up as do regis-
tries in Denmark. This meant that more in-depth exploration of the
association between HCTZ exposure and skin cancer outcome could
not be provided using the current data. Despite these differences, we
observed similar associations that do not appear to be explained by
common sources of heterogeneity including from differences in
healthcare delivery or data recording. We also adjusted for missing
potential confounders of smoking and BMI. Although these are per-
haps stronger confounders for the lip and oral cavity cancer outcomes
it has recently been reported that smoking is inversely associated with
melanoma development, an effect that we also observed in our
study.23,24
BMI was evaluated because it has been shown to influence a
wide range of cancer development or progression including mela-
noma.25,26 We observed other significant inverse associations with
BMI of 30 or greater for all cancers apart from lip cancer, the reasons
for which are uncertain. Whilst adjustment for these may have only
TABLE 4 Absolute risk of squamous cell carcinoma, basal cell
carcinoma and lip cancer with high dose cumulative
hydrochlorothiazide exposure overall and stratified by age and sex
categories
Cancer type
Adjusted rate difference
per 100 000 person years
Number needed to
harm per year
SCC with ≥50 000 mg cumulative dose
▪ overall 124.4 (56.5–231.3) 804
▪ male 219.8 (99.7–408.4) 455
▪ female 71.3 (32.4–132.6) 1402
▪ aged
40–59 y
24.0 (10.9–44.6) 4167
▪ aged 60 y
and over
383.4 (173.9–712.5) 261
BCC with ≥50 000 mg cumulative dose
▪ overall 40.6 (32.2–51.3) 2463
▪ male 52.4 (41.4–66.1) 1909
▪ female 31.1 (24.6–39.2) 3216
▪ aged
40–59 y
27.7 (21.9–34.9) 3610
▪ aged 60 y
and over
161.9 (128.1–204.2) 618
Lip cancer with 1–24 999 mg cumulative dose*
▪ overall 0.5 (0.3–1.2) 20 0000
▪ male 0.8 (0.4–1.7) 125 000
▪ female 0.4 (0.2–0.9) 250 000
▪ aged
40–59 y
0.2 (0.1–0.4) 500 000
▪ aged 60 y
and over
2.7 (1.2–5.8) 37 037
SCC = squamous cell carcinoma skin cancer; BCC = basal cell carcinoma
skin cancer.
*Lip cancer adjusted rate difference = calculated with significant model 2
estimates using a 5-year lag-time.
BCC adjusted rate difference = calculated with significant model 2
estimates using a 2-year lag-time.
SCC adjusted rate difference = calculated using the IRR and published UK
incidence rates for SCC.3
TABLE 5 Associations between different skin, lip and oral cavity cancer and smoking and BMI
SCC IRR BCC IRR Melanoma IRR Lip cancer IRR Oral cavity cancer IRR
Smoking
Nonsmoker 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
Ex-smoker 0.91 (0.86–0.97) 0.97 (0.95–0.99) 0.93 (0.89–0.97) 1.37 (1.08–1.74) 1.15 (1.04–1.27)
Current smoker 0.98 (0.90–1.06) 0.75 (0.72–0.75) 0.65 (0.61–0.69) 3.48 (2.75–4.42) 2.63 (2.34–2.96)
Body mass index (kg/m2)
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
25–29.9 1.01 (0.95–1.07) 0.94 (0.92–0.96) 1.04 (0.99–1.09) 0.96 (0.78–1.18) 0.81 (0.73–0.89)
≥30 0.79 (0.74–0.84) 0.75 (0.73–0.76) 0.92 (0.87–0.98) 1.10 (0.88–1.38) 0.73 (0.65–0.82)
IRR = incidence rate ratios following adjusted for all confounders in contained in model 2.
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slightly influenced the size of the effect estimates for HCTZ it had
negligible impact on their statistical significance suggesting that, in
this instance at least, missing data on these characteristics may not be
critical for similar studies examining HCTZ exposure where informa-
tion on smoking or BMI is not available. Other unmeasured con-
founding remains possible such as surveillance bias though we
observed no association with oral cavity cancer, which should be sub-
ject to similar issues. This provides stronger evidence that the
observed associations may be causal and related to photosensitivity.
Only relatively few oral cavity cancer cases were detected compared
to BCC, SCC or melanoma, meaning that associations between oral
cavity cancer and HCTZ may be less precise. However, the observed
associations with HCTZ were either close to the null or inversely asso-
ciated with oral cavity cancer, unlike with skin cancer, suggesting that
it is less likely that we are missing a significant association because of
insufficient power. The recent Danish studies used pathologically vali-
dated outcomes whilst THIN outcomes used primary care diagnostic
coding only. However, the incidence of each skin cancer in our studies
was similar to UK national cancer registrations, apart from SCC, where
incidence in primary care records was lower. This probably relates to
the use of Read codes that only specified squamous carcinoma as
being skin related in an attempt to improve validity. This will underes-
timate the absolute risk for SCC if it is calculated using our cohort
data, which is the reason we used published incidence rates for SCC
from the UK instead.3
4.2 | Implications for practice
In 2018, PRAC considered that it was biologically plausible that non-
melanoma skin cancer may occur following higher cumulative doses
of HCTZ, which resulted in special precautions being added to the
product information. This stated that patients taking HCTZ should be
informed of the risk of nonmelanoma skin cancer and advised to
check their skin and report suspicious lesions.27 Possible preventive
measures are also suggested such as limited exposure to sunlight and,
in case of exposure, adequate skin protection. This information was
communicated via a direct healthcare professional communication, a
common method of communicating safety warnings that may be asso-
ciated with greater impact compared to other communication
methods such as drug bulletins.28,29 Our studies were undertaken to
support the EMA PRAC assessment and provide further evidence
suggesting a causal association between exposure to HCTZ and non-
melanoma and lip cancers related to photosensitivity. The frequency
of these skin cancers in the HCTZ summary of product characteristics
in Europe is listed as not known. We estimated the number of addi-
tional cancers that may arise per year following cumulative HCTZ
exposure after the procedure was closed. For all cancer types, it is
notable that absolute risk from cumulative HCTZ exposure is much
greater in those aged over 60 years. There was some evidence that
absolute risk was also greater in men. This information may potentially
support an update to the product information regarding the frequency
of such events. Further studies examining the risk of skin cancer with
HCTZ in different UV-susceptible skin susceptible populations are
required to assess whether these effects are more generalizable, simi-
lar to the recently published study using data from Taiwan.30
5 | CONCLUSIONS
In a UK population, evidence suggests that exposure to HCTZ was
associated with an increased risk of incident nonmelanoma skin and
lip cancers. This information may be useful to healthcare professionals
for assessing the benefit–risk and communicating the risk of these
medicines to patients.
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